Eliem Therapeutics, Inc.

NasdaqGM:ELYM Stock Report

Mkt Cap: US$102.3m

Eliem Therapeutics Financial Health

How is Eliem Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ELYM's short term assets ($133.2M) exceed its short term liabilities ($6.3M).

Long Term Liabilities: ELYM's short term assets ($133.2M) exceed its long term liabilities ($219.0K).


Debt to Equity History and Analysis

Debt Level: ELYM is debt free.

Reducing Debt: ELYM has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ELYM has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ELYM has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 53.4% each year.


Discover healthy companies